1. Home
  2. NAMS vs IAC Comparison

NAMS vs IAC Comparison

Compare NAMS & IAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • IAC
  • Stock Information
  • Founded
  • NAMS 2019
  • IAC N/A
  • Country
  • NAMS Netherlands
  • IAC United States
  • Employees
  • NAMS N/A
  • IAC N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • IAC Computer Software: Programming Data Processing
  • Sector
  • NAMS Health Care
  • IAC Technology
  • Exchange
  • NAMS Nasdaq
  • IAC Nasdaq
  • Market Cap
  • NAMS 2.9B
  • IAC 3.1B
  • IPO Year
  • NAMS N/A
  • IAC 1992
  • Fundamental
  • Price
  • NAMS $25.07
  • IAC $35.46
  • Analyst Decision
  • NAMS Strong Buy
  • IAC Strong Buy
  • Analyst Count
  • NAMS 9
  • IAC 14
  • Target Price
  • NAMS $41.00
  • IAC $49.50
  • AVG Volume (30 Days)
  • NAMS 843.1K
  • IAC 1.5M
  • Earning Date
  • NAMS 08-06-2025
  • IAC 08-04-2025
  • Dividend Yield
  • NAMS N/A
  • IAC N/A
  • EPS Growth
  • NAMS N/A
  • IAC N/A
  • EPS
  • NAMS N/A
  • IAC N/A
  • Revenue
  • NAMS $64,006,000.00
  • IAC $3,705,967,000.00
  • Revenue This Year
  • NAMS N/A
  • IAC N/A
  • Revenue Next Year
  • NAMS $73.09
  • IAC $0.56
  • P/E Ratio
  • NAMS N/A
  • IAC N/A
  • Revenue Growth
  • NAMS 762.15
  • IAC 8.11
  • 52 Week Low
  • NAMS $14.06
  • IAC $32.05
  • 52 Week High
  • NAMS $27.29
  • IAC $45.45
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 61.96
  • IAC 40.11
  • Support Level
  • NAMS $24.73
  • IAC $33.73
  • Resistance Level
  • NAMS $25.80
  • IAC $35.72
  • Average True Range (ATR)
  • NAMS 1.33
  • IAC 1.33
  • MACD
  • NAMS 0.17
  • IAC -0.32
  • Stochastic Oscillator
  • NAMS 83.46
  • IAC 39.94

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About IAC IAC Inc.

IAC Inc is comprised of businesses including Angi Inc, Dotdash Meredith and Care.com, among many others ranging from early stage to established businesses. Its Dotdash Meredith segment consists of its Digital and Print businesses. Angi segment offers repairing and remodeling homes to cleaning and landscaping services. Care.com segment is a online destination for families to connect with caregivers for their children, aging parents, pets and homes and for caregivers to connect with families seeking care services. Search segment consists of a collection of websites providing general search services and information, and a Desktop business, which includes business-to-business partnership operations.

Share on Social Networks: